| Institution: | 1. Department of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia;2. Melanoma, Cancer Immunotherapy, and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Via Mariano Semmola, 80131 Napoli, Italy;1. Division of Medical Oncology, Department of Medicine, Harvard Medical School, Boston, Massachusetts;2. Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan;1. Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, Arizona;2. Southwest Skin Specialists, Phoenix, Arizona;1. Foundation Medicine, Inc, Cambridge, MA;2. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH;1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China;2. Sun Yat-sen University Cancer Center, Guangzhou, China;3. Yonsei University College of Medicine, Seoul, South Korea;4. Zhejiang Cancer Hospital, Hangzhou, China;5. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan;6. Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea;7. Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand;8. Rajavithi Hospital, Bangkok, Thailand;9. Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong, China;10. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;11. China Novartis Institutes for BioMedical Research, Beijing, China;12. Department of Urology and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China |
